Home | Blood, Heart and Circulation | Injection lowers cholesterol in preliminary human trial

Injection lowers cholesterol in preliminary human trial

Study Highlights: - In its first preliminary tests in humans, an injectable medication lowered bad cholesterol in healthy volunteers. - The substance disables a protein that interferes with the liver’s ability to remove bad cholesterol from the blood. - If it proves safe and effective, the new approach could help people who are unable to control their cholesterol levels with current medications.

ORLANDO, FLA. — Patients unable to control their cholesterol levels with medications may someday be able to lower their “bad” cholesterol with a shot, according to research presented at the American Heart Association’s Scientific Sessions 2011.
 
In its first preliminary human tests, the medicine in the new shot lowered low density lipoprotein, or “bad” cholesterol, in healthy volunteers who received the highest dose an average 64 percent more than those who received an inactive placebo injection.
 
The injected material — targeting a recently-identified cholesterol regulator — is a monoclonal antibody that’s a laboratory-made human protein. Monoclonal antibodies are already used to treat certain cancers and other medical conditions.
 
In the study, scientists created the monoclonal antibody AMG145 to disable the cholesterol regulator PCSK9, which interferes with the liver’s ability to remove bad cholesterol from the blood. Therefore, turning it off improves cholesterol levels.
 
“PCSK9 is the first target in lipid metabolism to be inhibited using a monoclonal antibody, and it appears to be a promising way to lower bad cholesterol,” said Clapton Dias, Ph.D., lead researcher and medical sciences director of clinical pharmacology and early development at Amgen, Inc., in Thousand Oaks, Ca.
 
The study involved 54 men and two women, 18 to 45 years old, who were healthy and not taking other medications. Participants received a single injection that contained one of five doses of AMG145 or a placebo. Sixteen received the injections intravenously and the others got simple injections that delivered the drug just underneath the skin.
 
After the injections, bad cholesterol was measured frequently for 85-113 days, along with other laboratory measures related to heart disease.
 
With increasing doses of AMG145, blood tests revealed:
  • Less of the active form of PCSK9;
  • Lower levels of bad cholesterol, total cholesterol and apo-B (the primary protein component of bad cholesterol);
  • No effect on triglycerides, high density lipoprotein (“good” cholesterol) or a protein associated with good cholesterol — all lipid measures were not influenced by the PCSK9 regulator.
 “The more PCSK9 was lowered, the more bad cholesterol levels went down,” Dias said. “With higher doses, bad cholesterol stayed lower for a longer period.”
 
The injections were tolerated well, with volunteers receiving AMG145 experiencing no more side effects than those receiving the placebo.
The study included a small number of participants, and they were healthy.  So the company is conducting a similar study that gives multip
ple doses of AMG145 to adults who take statin medication to control their cholesterol.
 
If AMG145 proves safe and effective in further clinical trials, it could help people unable to control their cholesterol with current medications that work in different ways.
 
Co-authors are: Adam Shaywitz, M.D., Ph.D.; Brian Smith, Ph.D.; Maurice Emery, Pharm.D., Ph.D.; Bing Gao, M.S.; John Gibbs, Ph.D.; Bill Wishner, M.D.; Dina Stolman, M.D.; Caroline Crispino, Ph.D.; Blaire Cooke, Pharm. D.; Alex Colbert, Ph.D.; Marc Retter, M.D.; Ren Xu, Ph.D. and Mark Matson, M.D.
 
Author disclosures are on the abstract. Amgen, Inc. funded the study.
 
###
 
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position.  The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events.  The association has strict policies to prevent these relationships from influencing the science content.  Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding. External link
 
NR11-1138 (SS11/Dias)
 
NEW for Scientific Sessions 2011:
All downloadable video/audio interviews, B-roll, animation and images related to this news release are located on the right column of the release link 
http://newsroom.heart.org/pr/aha/_prv-injection-lowers-cholesterol-in-217779.aspx, along with general Sessions multimedia resources. Video clips with researchers/authors of studies will be added to the release links after embargo.   
 
Follow news from AHA Scientific Sessions 2011 via Twitter:  http://twitter.com/#!/heartnews External link. Follow  #AHANews2011. 
 
For Media Inquiries:
AHA News Media in Dallas: (214) 706-1396
AHA News Media Office, Nov. 12-16
at the Orange County Convention Center: (407) 685-5410
For Public Inquiries:  (800)-AHA-USA1 (242-8721)

Subscribe to comments feed Comments (0 posted)

total: | displaying:

Post your comment

  • Bold
  • Italic
  • Underline
  • Quote

Please enter the code you see in the image:

Captcha
  • Email to a friend Email to a friend
  • Print version Print version
  • Plain text Plain text

Tagged as:

No tags for this article

Rate this article

0